Neo-adjuvant chemotherapy sensitivity and associated gene expressions in cervical cancer
10.3760/cma.j.issn.1006-9801.2011.03.003
- VernacularTitle:子宫颈癌新辅助化疗敏感性及其相关基因表达的研究
- Author:
Jinghua LI
;
Haimei SUN
;
Weihong ZHAO
;
Baojun YANG
;
Limin FENG
- Publication Type:Journal Article
- Keywords:
Uterine cervical neoplasms;
Antineoplsstic combined chemotherapy protocols;
Gene expression
- From:
Cancer Research and Clinic
2011;23(3):154-156,160
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the associations between neo-adjuvant chemotherapy (NACT)sensitivity and expression of relative proliferation and apoptosis genes in cervical cancer tissues. Furthermore,the potential roles of relative genes expression as monitor in the chemotherapy against cervical cancer tissues were studied. Methods Fifteen pathologically proved Ⅱ A stage cervical cancer patients with HPV 16 positive were divided into effective group and non-effective group according to the clinical response to NACT, the changes of HPV16-E6, p53 genes and proteins expressions were measured by real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot. At the same time, MTT assay was used to detected proliferative activity to paclitaxel liposome and carboplatin (paraplatin) in HeLa cells. Results In effective group, the overall response rate was 73.3 % (11/15) and the HPV16-E6 mRNA and protein level after NACT was significantly decreased than that before NACT (t=3.359, t=3.614, P＜0.05), while p53mRNA and protein level increased significantly (t =5.852, t=2.838, P ＜0.05). However, there have no significant different between pre-NACT and Post-NACT of the two genes in the non-effective group. After using chemotherapy HeLa cells growth decreased. Conclusion HPV16-E6 and p53 expreesion level are useful paraneters in evaluating NACT response in cervical cancer tissues. The detection of the two genes expression is a method for predicting efficacy in NACT.
